Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Michael Bidder who wrote (1669)	1/14/1998 8:48:00 AM
From: Linda Kaplan	Respond to of 7041

Headline: Asensio & Company: Zonagen's Vasomax Patent Application Exposed ====================================================================== NEW YORK, Jan. 14 /PRNewswire/ -- Asensio & Company issued the following statement today: Zonagen, Inc. (BB: ZONA) has not disclosed the contents of its U.S. Vasomax patent application. However, Zonagen also filed an International Application under the Patent Cooperation Treaty that includes the Vasomax formulation. This application is publicly available and contradicts Zonagen's Vasomax discovery claims. The application confirms that Vasomax's only active ingredient is unaltered generic phentolamine. It also reveals that Vasomax contains no ingredient that can alter phentolamine's chemistry or its effects on the circulatory system. In fact, 212 mg of Vasomax's total 400 mg tablet is lactose, commonly known as milk sugar. Last Friday, Asensio & Company released a report on charges that Zonagen had filed a fraudulent ImmuMAX patent application and had failed to disclose it had been rejected. Despite this, Zonagen continued to promote ImmuMAX to investors and attempted to sell ImmuMAX rights to several companies including Schering-Plough. Likewise, Zonagen filed a Vasomax patent application despite having made no discovery and the prior existence of extensive phentolamine MED studies and products. A complete report on Zonagen's Vasomax patent application, including a description of Vasomax's ingredients and formulation, is available on Asensio & Company, Inc.'s home page located on the Internet at asensio.com . The report on Zonagen's ImmuMAX patent and discovery fraud charges and a complete Zonagen research report are also available at Asensio's Internet site in its Current Reports section under Zonagen. Asensio & Company maintains a Strong Sell recommendation on Zonagen shares. SOURCE Asensio & Company, Inc. -0- 01/14/98 /CONTACT: Manuel P. Asensio of Asensio & Company, 212-702-8800/

To: Michael Bidder who wrote (1669)	1/14/1998 8:49:00 AM
From: Myron David Kor	Respond to of 7041

Bidder: Asensio is a God and only he knows the truth! Wexler: Zonagen is a fraud and scam! Just like grade school, how many times must I be punished and listen to the same repetitive crap. I believe we are dealing with Intelligent Quotients about as high as their blood urea nitrogen provided the two of them are not in kidney failure.

To: Michael Bidder who wrote (1669)	1/14/1998 9:21:00 AM
From: Cosmo Daisey	Read Replies (2) \| Respond to of 7041

Mike, >>>>Also if this really is bogus and goes into the low single digits as predicted... 1 Will the touts on this thread be hauled into court? Any opinions? 2 What will precipitate a class action lawsuit. >>>> 1. I hope the touts are safe from lawsuits. This is an opinion board and to try and single someone out would damage the process we have here of sharing information. I hope the shorts are safe as well. I have heard of threats from the companies involved against posters on SI. Thats the point of anominity. Touts? Get better information and post it. 2. A class action suit may result if a large stock holder has been damaged by the decline in stock price and managment has withheld information about the investment risks. 3. Free exchange of information is essential without the threat of lawsuits. 4. Will every word of all your posts stand the test of accuracy? Cosmo